参考文献

［1］LEROITH D，BIESSELS G J，BRAITHWAITE S S，et al.Treatment of Diabetes in Older Adults:An Endocrine Society Clinical Practice Guideline［J］.J Clin Endocrinol Metab，2019，104（5）：1520-1574.

［2］BATTELINO T，DANNE T，BERGENSTAL R M，et al.Clinical Targets for Continuous Glucose Monitoring Data Interpretation:Recommendations From the International Consensus on Time in Range［J］.Diabetes Care，2019，42（8）：1593-1603.

［3］AMERICAN DIABETES ASSOCIATION.（6）Glycemic targets［J］.Diabetes Care，2015，38（Suppl）：S33-S40.

［4］NATHAN D M，BAYLESS M，CLEARY P，et al.Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years:advances and contributions［J］.Diabetes，2013，62（12）：3976-3986.

［5］VIGERSKY R A，FONDA S J，CHELLAPPA M，et al.Short-and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes［J］.Diabetes Care，2012，35（1）：32-38.

［6］BECK R W，BERGENSTAL R M，RIDDLESWORTH T D，et al.Validation of time in range as an outcome measure for diabetes clinical trials［J］.Diabetes Care，2019，42（3）：400-405.

［7］LU J Y，MA X J，SHEN Y，et al.Time in range is associated with carotid intimamedia thickness in type 2 diabetes［J］.Diabetes Technol Ther，2020，22（2）：72-78.

［8］BECK R W，BERGENSTAL R M，CHENG P，et al.The relationships between time in range，hyperglycemia metrics，and HbA _1c ［J］.J Diabetes Sci Technol，2019，13（4）：614-626. k5njcaPOOAdCwajZGwtz7lO3N5xAJev0ohGEfOdJ0jxNceHMkRLWdQVi+TQNz1N/